Document Detail


Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer.
MedLine Citation:
PMID:  12504047     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: Maximal therapeutic gain in xenograft sarcoma and toxicity for jejunal mucosa is time dependent for concurrent gemcitabine and radiotherapy (RT). We used a time-dependent schedule to determine the maximal-tolerated dose and dose-limiting toxicities (DLTs; Grade 4 hematologic or Grade 3 other toxicity). METHODS AND MATERIALS: Patients with pancreatic cancer (n = 33), periampullary carcinoma (n = 1), or bile duct cancer (n = 2) were treated with 3-day conformal RT with 50.4 Gy (tumor, lymphatics) plus a 5.4-Gy boost. Concurrent cisplatin (20 mg/m(2)/d on Days 1-5 and 29-33) and gemcitabine (initially 600 mg/m(2), weekly on Fridays 68 h before RT) were administered. Because of DLT, the doses were reduced to 500 mg/m(2) weekly and then 500, 400, or 300 mg/m(2) on Days 2, 5, 26, 33. RESULTS: DLT occurred at all dose levels of gemcitabine >300 mg/m(2). Fourteen patients were treated at the recommended Phase II dose of gemcitabine (300 mg/m(2)) without DLT. The response to chemoradiation allowed 10 of 30 initially unresectable patients with primary pancreatic carcinoma to undergo radical surgery, including a complete response in 2 cases. CONCLUSIONS: At the recommended Phase II dose, chemoradiation with gemcitabine and cisplatin can be administered safely in pancreatic carcinoma. However, at higher dose levels, toxicity is severe and frequent. Patients with a chance for conversion to resection could benefit from this schedule.
Authors:
Thomas B Brunner; Gerhard G Grabenbauer; Peter Klein; Ulrich Baum; Thomas Papadopoulos; Werner Bautz; Werner Hohenberger; Rolf Sauer
Related Documents :
6365497 - Important considerations for the clinical evaluation of drugs: appropriate dosing regim...
10572607 - Saturable metabolism of continuous high-dose ifosfamide with mesna and gm-csf: a pharma...
12011137 - Phase i and pharmacokinetic study of novel l-nucleoside analog troxacitabine given as a...
9738567 - Phase i trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhi...
17432377 - Floc size distributions in dissolved air flotation of winnipeg tap water.
12852707 - Comparison of treatment with fluvastatin extended-release 80-mg tablets and immediate-r...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase I; Journal Article    
Journal Detail:
Title:  International journal of radiation oncology, biology, physics     Volume:  55     ISSN:  0360-3016     ISO Abbreviation:  Int. J. Radiat. Oncol. Biol. Phys.     Publication Date:  2003 Jan 
Date Detail:
Created Date:  2002-12-30     Completed Date:  2003-01-28     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  7603616     Medline TA:  Int J Radiat Oncol Biol Phys     Country:  United States    
Other Details:
Languages:  eng     Pagination:  144-53     Citation Subset:  IM    
Affiliation:
Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. TBrunner@mail.med.upenn.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Blood Cells / drug effects,  radiation effects
Cisplatin / administration & dosage
Combined Modality Therapy
Deoxycytidine / administration & dosage,  analogs & derivatives*
Digestive System / drug effects
Female
Humans
Male
Maximum Tolerated Dose
Middle Aged
Pancreatic Neoplasms / mortality,  pathology,  therapy*
Radiotherapy / adverse effects
Radiotherapy Dosage
Chemical
Reg. No./Substance:
103882-84-4/gemcitabine; 15663-27-1/Cisplatin; 951-77-9/Deoxycytidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sites of local recurrence after surgery, with or without chemotherapy, for rectal cancer: implicatio...
Next Document:  Prospective comparison of breast pain in patients participating in a randomized trial of breast-cons...